- Home
- SEER vs SPRO Comparison
SEER vs SPRO Comparison
Compare SEER & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- SPRO
- Stock Information
- Founded
- SEER 2017
- SPRO 2013
- Country
- SEER United States
- SPRO United States
- Employees
- SEER N/A
- SPRO N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- SPRO Health Care
- Exchange
- SEER Nasdaq
- SPRO Nasdaq
- Market Cap
- SEER 113.8M
- SPRO 121.0M
- IPO Year
- SEER 2020
- SPRO 2017
- Fundamental
- Price
- SEER $2.04
- SPRO $1.88
- Analyst Decision
- SEER
- SPRO Buy
- Analyst Count
- SEER 0
- SPRO 4
- Target Price
- SEER N/A
- SPRO $5.00
- AVG Volume (30 Days)
- SEER 134.9K
- SPRO 357.1K
- Earning Date
- SEER 11-05-2025
- SPRO 11-13-2025
- Dividend Yield
- SEER N/A
- SPRO N/A
- EPS Growth
- SEER N/A
- SPRO N/A
- EPS
- SEER N/A
- SPRO N/A
- Revenue
- SEER $16,288,000.00
- SPRO $48,576,000.00
- Revenue This Year
- SEER $27.77
- SPRO N/A
- Revenue Next Year
- SEER $20.28
- SPRO N/A
- P/E Ratio
- SEER N/A
- SPRO N/A
- Revenue Growth
- SEER 10.52
- SPRO N/A
- 52 Week Low
- SEER $1.62
- SPRO $0.51
- 52 Week High
- SEER $2.63
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- SEER 46.20
- SPRO 38.41
- Support Level
- SEER $1.97
- SPRO $1.91
- Resistance Level
- SEER $2.10
- SPRO $2.18
- Average True Range (ATR)
- SEER 0.05
- SPRO 0.10
- MACD
- SEER 0.00
- SPRO 0.00
- Stochastic Oscillator
- SEER 43.75
- SPRO 13.70
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.